Wednesday, 24 May 2017
Latest news
Main » Hot Stock of this Morning: Bristol-Myers Squibb Company (NYSE:BMY)

Hot Stock of this Morning: Bristol-Myers Squibb Company (NYSE:BMY)

23 February 2017

The latest exchange of 24.46 Million shares is below its average trading activity of 24.76 Million shares. BlackRock Institutional Trust Company N.A. boosted its position in shares of Bristol-Myers Squibb Company by 5.7% in the third quarter. Samuels joined the board earlier this year at drugmaker Perrigo Co, which later struck a deal with activist Starboard Value LP two weeks ago to add 3 more directors.

Many analysts are providing their Estimated Earnings analysis for Bristol-Myers Squibb Company and for the current quarter 14 analysts have projected that the stock could give an Average Earnings estimate of $0.75/share. The company's shares were closed at $54.78. Institutional investors and hedge funds own 69.67% of the company's stock. The stock is trading $55.03 its 50-day moving average by 0.25%.

For the current quarter, the highest estimate analysts provided is 4.92 Billion and the lowest is 4.55 Billion.

Bristol-Myers Squibb Company (NYSE:BMY) shares have been labeled a top pick by Beta Research as it meets the A+ criteria outlined by the firm. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.67 by $0.04. The average revenue estimate for the year ending December 2017 is $19.72B by 21 analysts.

10/10/2016 - Bristol-Myers Squibb Company had its "hold" rating reiterated by analysts at SunTrust. Jana started pushing for management change when the company released their yearly earnings and stated that they would not pursue an accelerated regulatory pathway for their first-line therapy, and instead for a broad program that combines their product with chemotherapy. During the same quarter in the previous year, the firm posted $0.38 earnings per share.

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 1st.

Interim estimates of 2016-17 seasonal influenza vaccine effectiveness
They feel they have good results and they said it is not too late for people to get the shot. Flu season is in full swing but should calm down around the end of March, beginning of April.

Heading into the stock price potential, Bristol-Myers Squibb Company needs to grow just 0.4% to cross its median price target of $55. This represents a $1.56 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date of this dividend was Wednesday, January 4th. Bristol-Myers Squibb Company's dividend payout ratio (DPR) is now 58.87%.

This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally stolen and reposted in violation of worldwide copyright and trademark law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/02/22/ffcm-llc-invests-2534000-in-bristol-myers-squibb-company-bmy.html.

Several analysts are now covering the company.

11/07/2016 - Bristol-Myers Squibb Company had its "buy" rating reiterated by analysts at Citigroup. BMO Capital Markets decreased their target price on shares of Bristol-Myers Squibb Company from $60.00 to $56.00 and set a "market perform" rating for the company in a research report on Monday, October 24th. Deutsche Bank AG dropped their target price on shares of Bristol-Myers Squibb Company from $59.00 to $52.00 and set a "hold" rating for the company in a research note on Friday, October 28th.

08/08/2016 - Bristol-Myers Squibb Company had its "buy" rating reiterated by analysts at William Blair. According to Thomson Reuters, sell-side analysts are forecasting a harmony target price of $139.82 on company shares. Back on Aug 08, 2016, a downgrade report came from equity analysts at Credit Suisse who in their research findings assigned Neutral rating on the stock.

Hot Stock of this Morning: Bristol-Myers Squibb Company (NYSE:BMY)